Effect of chronic dexfenfluramine on Fos in rat brain

Brain Research

Volumn 728, Issue 2, 1996, Pages 188-192

  Li, Bai Han ^a,b   Rowland, Neil E ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Anorectic agent; Cholecystokinin; Drug tolerance; Escalating dose regimen; Paraventricular hypothalamus; Serotonin

Indexed keywords

5 CARBAMOYLTRYPTAMINE; CHOLECYSTOKININ; DEXFENFLURAMINE; SEROTONIN; SEROTONIN AGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN REGION; CONTROLLED STUDY; DRUG TOLERANCE; IMMUNOHISTOCHEMISTRY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; ONCOGENE C FOS; PRIORITY JOURNAL; RAT; SEROTONIN RELEASE; SUBCUTANEOUS DRUG ADMINISTRATION; THALAMUS MIDLINE NUCLEUS;

EID: 0030605869     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00397-6     Document Type: Article

References (21)

1. [1] Appel, N.M., Contrera, J.F. and De Souza, E.B., Fenfluramine selectively and differentially decreases the density of serotonergic nerve terminals in rat brain: evidence from immunocytochemical studies, J. Pharmacol. Exp. Ther., 249 (1989) 928-943.
2. [2] Caccia, S., Sarati, S., Anelli, M. and Garattini, S., Effect of escalating doses of D-fenfluramine on the content of indoles in brain, Neuropharmacology, 31 (1992) 875-879.
3. [3] Carlton, J. and Rowland, N.E., Anorexia and brain serotonin: development of tolerance to the effects of fenfluramine and quipazine in rats with serotonin-depleting lesions, Pharmac. Biochem. Behav., 20 (1984) 739-745.
4. [4] Kalia, M., Reversible, short-lasting, and dose-dependent effect of (+)-fenfluramine on neocortical serotonergic axons, Brain Res., 548 (1991) 111-125.
5. [5] Kleven, M.S., Schuster, C.R. and Seiden, L.S., Effect of depletion of brain serotonin by repeated fenfluramine on neurochemical and anorectic effects of acute fenfluramine. J. Pharmacol. Exp. Ther., 246 (1988) 822-828.
6. [6] Li, B.-H. and Rowland, N.E., Dexfenfluramine induces Fos-like immuno-reactivity in discrete brain regions in rats, Brain Res. Bull., 31 (1993) 43-48.
7. [7] Li, B.-H. and Rowland, N.B., Cholecystokinin-and dexfenfluramine-inducd anorexia compared using devazepide and c-fos expression in the rat brain, Regul. Peptides, 50 (1994) 223-233.
8. [8] Li, B.-H., Spector, A.C. and Rowland, N.E., Reversal of dexfenfluramine-induced anorexia and c-Fos/c-Jun expression by lesion in the lateral parabrachial nucelus, Brain Res., 640 (1994) 255-267.
9. [9] McTavish, D. and Heel, R.C., Dexfenfluramine: A review of its pharmacological properties and therapeutic potential in obesity, Drugs, 43 (1992) 713-733.
10. [10] Paxinos, G. and Watson, C., The Rat Brain in Stereotaxic Coordinates, 2nd edn., Academic Press, 1986.
11. [11] Raiteri, M., Bonanno, G. and Vallebuona, F., In vitro and in vivo effects of D-fenfluramine: no apparent relation between 5-hydroxytryptamine release and hypophagia, J. Pharmacol. Exp. Ther., 273 (1995) 643-649.
12. [12] Richard, D., Rivest, S. and Rivier, C., The 5-hydroxytryptamine agonist fenfluramine increases Fos-like immunoreactivity in the brain, Brain Res., 594 (1992) 131-137.
13. [13] Rowland, N.B., Tolerance to the anorectic effect of dexfenfluramine in rats: role of serotonin, cholecystokinin, and neuropeptide Y, Physiol. Behav., 55 (1994) 201-207.
14. [14] Rowland, N.B., Antelman, S.M. and Kocan, D., Differences among 'serotonergic' anorectics in a cross-tolerance paradigm: do they all act on serotonin systems? Eur. J. Pharmacol., 81 (1982) 57-66.
15. [15] Rowland, N.E. and Carlton, J., Neurobiology of an anorectic drug: fenfluramine, Prog. Neurobiol., 27 (1986) 13-62.
16. [16] Rowland, N.E. and Carlton, J., Tolerance to fenfluramine anorexia: fact or fiction? Appetite, 7 (1986) suppl. 71-83.
17. [17] Rowland, N.E. and Carlton, J., Dexfenfluramine: effects on food intake in various animal models, Clin. Neuropharmacol., 11 (1988) suppl 1. S33-S50.
18. [18] Rowland, N.E., Kalehua, A.N., Li, B.-H., Semple-Rowland, S.L. and Streit, W.J., Loss of serotonin uptake sites and immunoreactivity in rat cortex after dexfenfluramine occur without parallel glial cell reactions. Brain Res., 624 (1993) 35-43.
19. [19] Rowland, N.E., Li, B.-H., Fregly, M.J. and Smith, G.C., Involvement of angiotensin in water intake induced by peripheral administration of a serotonin agonist, 5-carboxyamidotryptamine, Brain Res., 664 (1994) 148-154.
20. [20] Simansky, K.J., 5-HT receptor subtypes influencing feeding and drinking: focus on the periphery. In S.J. Cooper and P.G. Clifton (Eds.), Drug Receptor Subtypes and Ingestive Behavior, Academic Press, London, 1996, pp. 59-97.
21. [21] Zaczek R., Battaglia, G., Culp, S., Appel, N.M., Contrera, J.F. and DeSousa, E.B., Effects of repeated fenfluramine administration on indices of monoamine function in rat brain: pharmacokinetic, dose response, regional specificity and time course data, J. Pharmacol. Exp. Ther., 253 (1990) 104-112.